Geneticure
PrivateLast Round
Seed
Oct 21, 2026
Total Funding Raised
$7.37M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Geneticure operates in Healthcare & Life Sciences and is based in Eden Prairie, Minnesota. Its latest recorded funding round was a Seed round in October 2026.
Geneticure is a biotechnology company that develops pharmacogenomic tests to guide personalized treatment for hypertension and other chronic diseases.
Sector
Healthcare & Life Sciences
Verticals
Precision Medicine, Biotechnology, Medical Devices
Business Model
B2B
Customer Profile
Usage-Based SaaS, Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Geneticure Comparables
Compare Geneticure with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| OneOme | 86% | |
| RxGenomix | 78% | |
| Sinochips Diagnostics | 77% |
For institutional investors. Book with your work email.
Geneticure Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Seed | Oct 21, 2026 | ||||
| Accelerator | Jul 12, 2023 | ||||
| Seed | May 18, 2021 | ||||
| Grant | May 14, 2020 | ||||
| Seed | Nov 14, 2019 | ||||
Seed | Apr 20, 2018 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Geneticure Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Western Skies Partners | Seed |
| M25 | Seed |
| Creative Destruction Lab | Accelerator |
| Rochester Area Economic Development, Inc. | Seed |
| Southeast Minnesota Capital Partners | Seed |
| Xcellerant Ventures | Seed |
| Wireframe Ventures | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Oct 21, 2026
$1M round led by Xcellerant Ventures.
- Aug 20, 2026
Monthly visitors increased 61% MoM.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- receives_financingOct 22, 2026
Geneticure, Inc. receives a $1M Fund I investment from Xcellerant Ventures on Oct 21st '26 in Arizona to accelerate commercial scaling and support a new clinical laboratory.
- expands_facilitiesOct 22, 2026
Geneticure, Inc. plans to establish a laboratory base in Southern Arizona, initially supporting sample accessioning in Tucson and adding research and development capabilities over time, as announced on Oct 21st '26.
For institutional investors. Book with your work email.
Geneticure Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Geneticure's valuation, stock price, and market status.
Is Geneticure a public or private company?
Geneticure is a private company.
What is the current stock price of Geneticure?
Geneticure is a private company, so its shares have no public market price. Caplight tracks Geneticure's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Geneticure worth (valuation)?
Valuation information for Geneticure is not publicly available.
Can I buy Geneticure stock?
Geneticure shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Geneticure's last funding round?
Geneticure's most recent funding round was Seed on October 21, 2026.
Who are the main investors in Geneticure?
Key investors in Geneticure include Xcellerant Ventures.
Will Geneticure IPO soon?
No public IPO plans have been announced for Geneticure.
How can I track Geneticure secondary market activity?
Caplight tracks bids, offers, and trades in Geneticure's shares on secondary markets.